ReviewAbdominal radiology (New York)2021
SBRT for HCC: Overview of technique and treatment response assessment.
Review in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pooled it
- A Phase II Study of Optimized Individualized Adaptive Radiotherapy for Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Feasibility of Conventional Abdominal Ultrasound for Monitoring Tumor Size After Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.Biomedicines · 2026Article
- Delayed Bile Duct Injury Preceded by Sepsis After Biliary Cooling-Assisted Ablation of Hilar Hepatocellular Carcinoma.ACG case reports journal · 2026Article
- Efficacy and safety of stereotactic body radiation therapy combined with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis:a multicenter propensity score matching study.Frontiers in oncology · 2026Article
- Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma.Clinical and translational radiation oncology · 2024Article
- Article
- Integrated analysis of lactate-related genes identifies POLRMT as a novel marker promoting the proliferation, migration and energy metabolism of hepatocellular carcinoma via Wnt/β-Catenin signaling.American journal of cancer research · 2024Article
- Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma.Abdominal radiology (New York) · 2023Review
- Proton Beam Therapy versus Radiofrequency Ablation for Patients with Treatment-Naïve Single Hepatocellular Carcinoma: A Propensity Score Analysis.Liver cancer · 2023Article
- Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy.Journal of clinical medicine · 2023Review
- Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Article
- Salvage locoregional therapies for recurrent hepatocellular carcinoma.World journal of gastroenterology · 2023Review
- Key changes in the future clinical application of ultra-high dose rate radiotherapy.Frontiers in oncology · 2023Article
- The Refined Application and Evolution of Nanotechnology in Enhancing Radiosensitivity During Radiotherapy: Transitioning from Gold Nanoparticles to Multifunctional Nanomaterials.International journal of nanomedicine · 2023Review
- Editorial commentary on Indian Journal of Gastroenterology-July-August 2021.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiation therapy (SBRT) is an emerging locoregional treatment (LRT) modality used in the management of patients with hepatocellular carcinoma (HCC). The decision to treat HCC with LRT is evaluated in a multidisciplinary setting, and the specific LRT chosen depends on the treatment intent, such as bridge-to-transplant, down-staging to transplant, definitive/curative treatment, and/or palliation, as well as underlying patient clinical factors. Accurate assessment of treatment response is necessary in order to guide clinical management in these patients. Patients who undergo LRT need continuous imaging evaluation to assess treatment response and to evaluate for recurrence. Thus, an accurate understanding of expected post-SBRT imaging findings is critical to avoid misinterpreting normal post-treatment changes as local progression or viable tumor. SBRT-treated HCC demonstrates unique imaging findings that differ from HCC treated with other forms of LRT. In particular, SBRT-treated HCC can demonstrate persistent APHE and washout on short-term follow-up imaging. This brief review summarizes current evidence for the use of SBRT for HCC, including patient population, SBRT technique and procedure, tumor response assessment on contrast-enhanced cross-sectional imaging with expected findings, and pitfalls in treatment response evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.